iShares Biotechnology ETF

IBB

iShares by BlackRock

Fact Sheet as of September 30, 2026

FUND DESCRIPTION

The iShares Biotechnology ETF seeks to track an index that includes U.S.-listed equities in the biotechnology sector. The fund offers a way to express a focused view on companies engaged in the research and development of therapeutic treatments.

GROWTH OF HYPOTHETICAL $10,000 SINCE INCEPTION

Fund (USD) Benchmark (USD)

The Growth of $10,000 chart reflects a hypothetical $10,000 investment and assumes reinvestment of dividends and capital gains. Fund expenses, including management fees and other expenses were deducted.

CALENDAR YEAR PERFORMANCE (%)

	2021	2022	2023	2024	2025
NAV	0.99	-13.59	3.62	-2.40	28.03
Market Price	0.95	-13.69	3.76	-2.41	27.98
Benchmark	1.37	-13.27	3.98	-2.11	28.46

ANNUALIZED PERFORMANCE (%)

	1y	3y	5y	10y	Since Inception
NAV	46.08	20.12	5.69	8.37	7.64
Market Price	46.12	20.14	5.69	8.38	7.64
Benchmark	46.67	20.51	6.05	8.74	-

The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted. Performance data current to the most recent month end may be obtained by visiting www.iShares.com or www.blackrock.com .

Beginning 8/10/20, the market price returns are calculated using the closing price. Prior to 8/10/20, the market price returns were calculated using the midpoint of the bid/ask spread at 4:00 PM ET. The returns shown do not represent the returns you would receive if you traded shares at other times.

RATINGS

MORNINGSTAR Bronze ★★★

Morningstar has awarded the Fund a BRONZE medal (Effective 08/31/2026).†

Analyst-Driven % : 20.00%

Data Coverage % : 100.00%

Overall Morningstar Rating for iShares Biotechnology ETF, as of 09/30/2026 rated against 160 Health Funds based on risk adjusted total return.††

KEY FACTS

Asset Class : Equity

Benchmark : NYSE Biotechnology Index

Fund Launch Date : 02/05/2001

Distribution Frequency : Quarterly

CUSIP : 464287556

Shares Outstanding : 53,200,000

Exchange : NASDAQ

Net Assets of Fund (M) : $11,196.65

FEES AND EXPENSES BREAKDOWN

Expense Ratio	0.44%
Management Fee	0.44%
Acquired Fund Fees and Expenses	0.00%
Other Expenses	0.00%

FUND CHARACTERISTICS

30 Day SEC Yield : -0.15%

Equity Beta (3y) : 0.69

P/B Ratio : 5.97x

P/E Ratio : 27.19x

Standard Deviation (3y) : 18.53%

Number of Holdings : 243

iShares Biotechnology ETF

iShares by BlackRock

TOP HOLDINGS (%)	
GILEAD SCIENCES	8.08%
AMGEN INC	7.78%
VERTEX PHARMACEUTICALS	7.62%
REGENERON PHARMACEUTICALS	5.28%
MODERNA	4.94%
NATERA	3.91%
ARGENX SE ADR	3.74%
ILLUMINA INC	2.89%
REVOLUTION MEDICINES	2.78%
BIOGEN	2.33%
Total of Portfolio	**49.35%**

Holdings are subject to change.

TOP SECTORS (%)	
	Fund
Biotechnology	87.20
Life Sciences Tools & Services	9.39
Pharmaceuticals	3.02
Health Care Services	0.14
Cash and/or Derivatives	0.14
Health Care Equipment	0.12
Food Retail	0.00

Allocations are subject to change.

iShares Biotechnology ETF

iShares by BlackRock

GLOSSARY

Equity Beta (3y): Beta is a measure of the tendency of securities to move with the market as a whole. A beta of 1 indicates that the security's price will move with the market. A beta less than 1 indicates the security tends to be less volatile than the market, while a beta greater than 1 indicates the security is more volatile than the market. Calculated vs. S&P 500.

P/E Ratio: The price to earnings ratio is a fundamental measure used to determine if an investment is valued appropriately. Each holdings' P/E is the latest closing price divided by the latest 12 months' earnings per share. Negative earnings are excluded, extraordinary items are excluded, and P/E ratios over 60 are set to 60.

Analyst-Driven %: Analyst Driven % is the analyst input into the overall rating assignment, including direct analyst coverage and inheritance of an analyst-rated pillar.

30 Day SEC Yield: A standard calculation of yield introduced by the SEC in order to provide fairer comparison among funds. This yield reflects the interest earned after deducting the fund's expenses during the most recent 30-day period by the average investor in the fund. Negative 30-Day SEC Yield results when accrued expenses of the past 30 days exceed the income collected during the past 30 days.

Number of Holdings: The number of holdings in the fund excluding cash positions and derivatives such as futures and currency forwards.

P/B Ratio: represents the ratio of the current closing price of the share to the latest quarter's book value per share.

Distribution Frequency: How often a distribution is paid by the fund. The most common distribution frequencies are annually, biannually and quarterly.

Data Coverage %: Data Coverage % is available input data for rating calculation at the Pillar level.

Standard Deviation (3y): Standard deviation measures how dispersed returns are around the average. A higher standard deviation indicates that returns are spread out over a larger range of values and thus, more volatile.

IMPORTANT INFORMATION:

Source: BlackRock, unless otherwise noted.

Carefully consider the Fund's investment objectives, risk factors, and charges and expenses before investing. This and other information can be found in the Fund's prospectus, and if available, summary prospectus, which may be obtained by calling 1-800-iShares (1-800-474-2737) or by visiting www.iShares.com or www.blackrock.com. Read the prospectus carefully before investing.
Investing involves risk, including possible loss of principal.

†The Morningstar Medalist Rating™ is the summary expression of Morningstar's forward-looking analysis of investment strategies as offered via specific vehicles using a rating scale of Gold, Silver, Bronze, Neutral, and Negative. The Medalist Ratings indicate which investments Morningstar believes are likely to outperform a relevant index or peer group average on a risk-adjusted basis over time. Investment products are evaluated on three key pillars (People, Parent, and Process) which, when coupled with a fee assessment, forms the basis for Morningstar's conviction in those products' investment merits and determines the Medalist Rating they're assigned. Pillar ratings take the form of Low, Below Average, Average, Above Average, and High. Pillars may be evaluated via an analyst's qualitative assessment (either directly to a vehicle the analyst covers or indirectly when the pillar ratings of a covered vehicle are mapped to a related uncovered vehicle) or using algorithmic techniques. Vehicles are sorted by their expected performance into rating groups defined by their Morningstar Category and their active or passive status. When analysts directly cover a vehicle, they assign the three pillar ratings based on their qualitative assessment, subject to the oversight of the Analyst Rating Committee, and monitor and reevaluate them at least every 14 months. When the vehicles are covered either indirectly by analysts or by algorithm, the ratings are assigned monthly. For more detailed information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures/. The Morningstar Medalist Ratings are not statements of fact, nor are they credit or risk ratings. The Morningstar Medalist Rating (i) should not be used as the sole basis in evaluating an investment product, (ii) involves unknown risks and uncertainties which may cause expectations not to occur or to differ significantly from what was expected, (iii) are not guaranteed to be based on complete or accurate assumptions or models when determined algorithmically, (iv) involve the risk that the return target will not be met due to such things as unforeseen changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rates, exchange rate changes, and/or changes in political and social conditions, and (v) should not be considered an offer or solicitation to buy or sell the investment product. A change in the fundamental factors underlying the Morningstar Medalist Rating can mean that the rating is subsequently no longer accurate.

††iShares Biotechnology ETF received a Morningstar Rating of 4 stars for the 3-year period, 3 stars for the 5-year period and 2 stars for the 10-year period, rated against 160, 153 and 121 Health Funds, respectively. Performance results represent past performance and are no guarantee of future results.
For each U.S.-domiciled fund with at least a 3-year history, Morningstar calculates a Morningstar RatingTM based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a fund's monthly performance (including the effects of sales charges, loads and redemption fees), placing more emphasis on downward variations and rewarding consistent performance. The top 10% of funds in each category receive five stars, the next 22.5% receive four stars, the next 35% receive three stars, the next 22.5% receive two stars and the bottom 10% receive one star. (Each share class is counted as a fraction of one fund within this scale and rated separately, which may cause slight variations in the distribution percentages.) The Overall Morningstar Rating for a fund is derived from a weighted-average of the performance figures associated with its 3-, 5- and 10-year (if applicable) Morningstar Rating metrics.
Morningstar Ratings are for the share classes cited only; other classes may have different ratings.

On 4/3/14, IBB changed to the total return version of the Nasdaq Biotechnology index from the price return version. Historical index data has been restated to the total return version of the index since index inception on 9/25/03. Historical index data prior to 9/25/03 reflects the price return version.
Funds that concentrate investments in specific industries, sectors, markets or asset classes may underperform or be more volatile than other industries, sectors, markets or asset classes and than the general securities market.
Diversification may not protect against market risk or loss of principal. Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the fund. Any applicable brokerage commissions will reduce returns.
Index returns are for illustrative purposes only. Index performance returns do not reflect any management fees or expenses. Indexes are

4989452

IMPORTANT INFORMATION:

unmanaged and one cannot invest directly in an index. Past performance does not guarantee future results.
"Acquired Fund Fees and Expenses" reflect the Fund's pro rata share of the indirect fees and expenses incurred by investing in one or more acquired funds, such as mutual funds, business development companies, or other pooled investment vehicles. AFFE are reflected in the prices of the acquired funds and thus included in the total returns of the Fund.
The iShares Funds are distributed by BlackRock Investments, LLC (together with its affiliates, "BlackRock").

The iShares Funds are not sponsored, endorsed, sold or promoted by ICE Data Indices, LLC, nor does this company make any representation regarding the advisability of investing in the Funds. BlackRock is not affiliated with ICE Data Indices, LLC.

BlackRock provides compensation in connection with obtaining or using third-party ratings and rankings.
© 2026 BlackRock, Inc. or its affiliates. All rights reserved. **iSHARES**, **iBONDS** and **BLACKROCK** are trademarks of BlackRock, Inc. or its affiliates. All other trademarks are those of their respective owners.

Not FDIC Insured - No Bank Guarantee - May Lose Value

Contact Us

For US: 1-800-474-2737 • ISHARES.COM

4989452